Trevi Therapeutics, Inc. TRVI Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost.
The official record: Trevi Therapeutics, Inc.’s 10-K, filed March 17, 2026, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s stock-based comp?
- Trevi Therapeutics, Inc. (TRVI) reported stock-based comp of $301K in Q4 2025.
- How has Trevi Therapeutics, Inc.'s stock-based comp changed year-over-year?
- Trevi Therapeutics, Inc.'s stock-based comp increased by 34.5% year-over-year, from $223.75K to $301K.
- What does stock-based comp mean?
- This metric quantifies the amount of share-based compensation expense that is not deductible for income tax purposes. It highlights the divergence between accounting expenses and tax-deductible expenses related to employee equity incentives. This helps investors understand the tax-shield limitations of stock-based compensation programs.